The data to be presented encompasses five of the company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 ...

A looming patent cliff is driving Big Pharma reorganization. Executives making career moves must understand differences in ...

Celebrating the best wholesale brokers in the USA who have been selected by the nation’s brokers for their ability to place ...